Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasms 16Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 6Endometrial Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Stomach Neoplasms 2Rectal Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lung Neoplasms 2Colonic Neoplasms 2Rhabdomyosarcoma 1Recurrence 1Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1Neuroblastoma 1Neoplasms by Site 1Hodgkin Disease 1Hepatoblastoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Ependymoma 1Digestive System Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1

Interventions

Bevacizumab 27Leucovorin 23Fluorouracil 22Oxaliplatin 17Irinotecan 15Cetuximab 14pembrolizumab 11IFL protocol 11Panitumumab 10Folfox protocol 10Capecitabine 10Gemcitabine 7adagrasib 5Cisplatin 5Carboplatin 5Ramucirumab 4Colonoscopy 4veliparib 3spartalizumab 3selpercatinib 3regorafenib 3labetuzumab 3durvalumab 3conatumumab 3cemiplimab 3Pemetrexed 3Paclitaxel 3HMPL-013 3Drug Therapy 35,11-methenyltetrahydrohomofolate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Colonic Neoplasms × dostarlimab × Clear all
NCT06567782 2026-05-22

AZUR-4

GlaxoSmithKline

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Colonic Neoplasms

NCT05855200 2026-01-23

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

GlaxoSmithKline

Phase 3 Recruiting
892 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡